CN107849136B - 抗TfR抗体及其在治疗增殖性和炎性疾病中的用途 - Google Patents

抗TfR抗体及其在治疗增殖性和炎性疾病中的用途 Download PDF

Info

Publication number
CN107849136B
CN107849136B CN201680040714.2A CN201680040714A CN107849136B CN 107849136 B CN107849136 B CN 107849136B CN 201680040714 A CN201680040714 A CN 201680040714A CN 107849136 B CN107849136 B CN 107849136B
Authority
CN
China
Prior art keywords
antibody
seq
protein
tfr
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680040714.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN107849136A (zh
Inventor
P·劳奈
C·贝兰格
H·苏谢
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inatherys
Original Assignee
Inatherys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inatherys filed Critical Inatherys
Publication of CN107849136A publication Critical patent/CN107849136A/zh
Application granted granted Critical
Publication of CN107849136B publication Critical patent/CN107849136B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN201680040714.2A 2015-07-22 2016-07-21 抗TfR抗体及其在治疗增殖性和炎性疾病中的用途 Active CN107849136B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306192.4 2015-07-22
EP15306192 2015-07-22
PCT/EP2016/067465 WO2017013230A1 (en) 2015-07-22 2016-07-21 ANTI-TfR ANTIBODIES AND THEIR USE IN TREATING PROLIFERATIVE AND INFLAMMATORY DISORDERS

Publications (2)

Publication Number Publication Date
CN107849136A CN107849136A (zh) 2018-03-27
CN107849136B true CN107849136B (zh) 2022-04-01

Family

ID=53776520

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680040714.2A Active CN107849136B (zh) 2015-07-22 2016-07-21 抗TfR抗体及其在治疗增殖性和炎性疾病中的用途

Country Status (22)

Country Link
US (2) US11230605B2 (enExample)
EP (1) EP3325509B1 (enExample)
JP (1) JP6858185B2 (enExample)
KR (1) KR102690998B1 (enExample)
CN (1) CN107849136B (enExample)
AU (1) AU2016296321B2 (enExample)
CA (1) CA2992509C (enExample)
CY (1) CY1123941T1 (enExample)
DK (1) DK3325509T3 (enExample)
ES (1) ES2860988T3 (enExample)
HR (1) HRP20210393T1 (enExample)
HU (1) HUE053296T2 (enExample)
IL (1) IL257065B (enExample)
LT (1) LT3325509T (enExample)
MX (1) MX2018000569A (enExample)
PL (1) PL3325509T3 (enExample)
PT (1) PT3325509T (enExample)
RS (1) RS61586B1 (enExample)
RU (1) RU2737637C2 (enExample)
SI (1) SI3325509T1 (enExample)
SM (1) SMT202100134T1 (enExample)
WO (1) WO2017013230A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL310251A (en) 2015-05-04 2024-03-01 Cytomx Therapeutics Inc Anti-cd71 antibodies, activatable anti-cd71 antibodies, compositions comprising same and uses thereof
FR3062213B1 (fr) 2017-01-20 2021-02-26 Endodiag Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose
EP3552631A1 (en) * 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
JP7611825B2 (ja) 2018-08-02 2025-01-10 ダイン セラピューティクス，インコーポレーテッド ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
WO2021092482A1 (en) 2019-11-06 2021-05-14 The Regents Of The University Of California Compositions and methods for transferrin receptor 1 targeting
US12624120B2 (en) 2020-01-31 2026-05-12 Dyne Therapeutics, Inc. Anti-transferrin receptor (TfR) antibody and uses thereof
WO2021154476A1 (en) * 2020-01-31 2021-08-05 Dyne Therapeutics, Inc. Anti-transferrin receptor (tfr) antibody and uses thereof
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
CN117980006A (zh) 2021-07-09 2024-05-03 达因疗法公司 用于治疗肌养蛋白病的肌肉靶向复合物和制剂
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
MX2024002753A (es) 2021-09-01 2024-05-20 Biogen Ma Inc Anticuerpos anti receptor de transferrina y usos de los mismos.
US20240376222A1 (en) * 2021-09-13 2024-11-14 The Board Of Regents Of The University Of Texas System Tfr antigen binding proteins and uses thereof
KR20250004770A (ko) 2022-04-15 2025-01-08 다인 세라퓨틱스, 인크. 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제
AU2023404617A1 (en) * 2022-12-02 2025-05-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-tfr1 antibodies and uses thereof
TW202444759A (zh) 2023-03-24 2024-11-16 美商戴納立製藥公司 Ａβ靶向蛋白及使用方法
EP4477236A1 (en) 2023-06-14 2024-12-18 Inatherys Combination therapy for treating a tumor using adc comprising anti-cd71 antibodies and bh3 mimetics
TW202517685A (zh) * 2023-10-26 2025-05-01 美商百健Ｍａ公司 抗運鐵蛋白受體抗體及其用途
WO2025140522A1 (en) * 2023-12-29 2025-07-03 Nona Biosciences (Suzhou) Co., Ltd. Anti-tfr1 antibodies, preparation methods and uses thereof
CN121517563A (zh) * 2024-08-09 2026-02-13 东北制药集团股份有限公司 人源化的靶向TfR1的抗体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111082A1 (en) * 2004-04-30 2005-11-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-tfr antibody.
WO2011073943A1 (fr) * 2009-12-16 2011-06-23 Centre National De La Recherche Scientifique (Cnrs) Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer
WO2014020140A1 (en) * 2012-08-02 2014-02-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of transferrin receptor antagonist for the treatment of thalassemia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434156A (en) 1981-10-26 1984-02-28 The Salk Institute For Biological Studies Monoclonal antibodies specific for the human transferrin receptor glycoprotein
KR100940380B1 (ko) * 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
WO2005011082A2 (en) 2003-07-23 2005-02-03 Univeral Infusion Technology Drive motor transmission system
AU2005252699B2 (en) * 2004-06-07 2010-12-23 Macrogenics West, Inc. Transferrin receptor antibodies
PL2161336T5 (pl) * 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
CA2893794C (en) * 2012-11-08 2021-11-09 University Of Miyazaki Antibody capable of specifically recognizing transferrin receptor
EP3552631A1 (en) * 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111082A1 (en) * 2004-04-30 2005-11-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-tfr antibody.
WO2011073943A1 (fr) * 2009-12-16 2011-06-23 Centre National De La Recherche Scientifique (Cnrs) Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer
WO2014020140A1 (en) * 2012-08-02 2014-02-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of transferrin receptor antagonist for the treatment of thalassemia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cloning and expression of a chimeric antibody directed against transferrin receptor;H R Hoogenboom等;《The Journal of Immunology》;19901231;全文 *
Identification of the transferrin receptor as a novel immunoglobulin(Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy.;Moura I C等;《The Journal of Expeimental Medicine》;20010820;第194卷(第4期);417-425 *

Also Published As

Publication number Publication date
KR20180028519A (ko) 2018-03-16
RS61586B1 (sr) 2021-04-29
RU2737637C2 (ru) 2020-12-01
US11230605B2 (en) 2022-01-25
JP2018521691A (ja) 2018-08-09
MX2018000569A (es) 2018-09-27
HK1256088A1 (en) 2019-09-13
EP3325509A1 (en) 2018-05-30
CA2992509A1 (en) 2017-01-26
JP6858185B2 (ja) 2021-04-14
PT3325509T (pt) 2021-03-12
RU2018106364A (ru) 2019-08-22
HRP20210393T1 (hr) 2021-04-30
IL257065B (en) 2022-07-01
DK3325509T3 (da) 2021-03-08
HUE053296T2 (hu) 2021-06-28
US20190092870A1 (en) 2019-03-28
RU2018106364A3 (enExample) 2019-08-22
CN107849136A (zh) 2018-03-27
BR112018000650A2 (en) 2018-09-18
PL3325509T3 (pl) 2021-07-19
EP3325509B1 (en) 2020-12-16
KR102690998B1 (ko) 2024-07-31
IL257065A (en) 2018-03-29
ES2860988T3 (es) 2021-10-05
US12037408B2 (en) 2024-07-16
CA2992509C (en) 2025-02-04
WO2017013230A1 (en) 2017-01-26
SI3325509T1 (sl) 2021-07-30
LT3325509T (lt) 2021-06-10
SMT202100134T1 (it) 2021-05-07
CY1123941T1 (el) 2022-05-27
US20220119543A1 (en) 2022-04-21
AU2016296321B2 (en) 2022-09-08
AU2016296321A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
US12037408B2 (en) Method of treating a tumor using anti-TfR antibodies
CA3092456C (en) Anti-tigit antibody and use thereof
CN109517065B (zh) Il-18结合分子
AU2024219504A1 (en) BINDING MOLECULES SPECIFIC FOR FCyGAMMA RIIA AND USES THEREOF
CA2977621C (en) Antibody binding to tfpi and composition comprising the same
JP7419238B2 (ja) Ｐｄ１結合剤
CA2904532A1 (en) Anti-cd25 antibodies and their uses
AU2014233503A1 (en) Anti-CD25 antibodies and their uses
CN117794948A (zh) 结合人纤维蛋白或纤维蛋白原γC结构域的抗体及其使用方法
US20170158755A1 (en) Anti-laminin4 antibodies specific for lg1-3
CA3092526A1 (en) Anti c-met antibodies
CN121758618A (zh) Pd1和vegfr2双结合剂
JP2021514654A (ja) Ｃｓｆ１ｒ結合剤
CN117295762A (zh) 抗cd122抗体及其用途
HK1256088B (en) Anti-tfr antibodies and their use in treating proliferative and inflammatory disorders
AU2023361530A1 (en) Vegf antibodies
BR112018000650B1 (pt) Anticorpos anti-trf e sua utilização no tratamento de transtornos proliferativos e inflamatórios

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant